RICHMOND, Calif., May 10, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will participate in the following upcoming conferences.

https://photos.prnewswire.com/prnvar/20130102/SF35903LOGO



    --  Piper Jaffray GenomeRx Symposium, New York, NY, May 17-18, 2016Mr.
        Lanphier will participate in two panel discussion entitled "Approaches
        to Gene Integration: Lenti, AAV & More" and "The Cutting/Editing Edge"
        on May 17, 2016.

    --  11(th) Annual World Stem Cells & Regenerative Medicine Congress, London,
        UK, May 18-20, 2016Mr. Lanphier will lead a roundtable discussion
        focused on infectious diseases on May 19, 2016.

About Sangamo

Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures(®) for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company's proprietary In Vivo Protein Replacement Platform(TM) (IVPRP) approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders. Based on its proprietary IVPRP approach, Sangamo is initiating Phase 1/2 clinical trials for hemophilia B, the first in vivo genome editing application cleared by the FDA, and MPS I. In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics(®) for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.

ZFP Therapeutic(®) is a registered trademark of Sangamo BioSciences, Inc.

Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-biosciences-announces-participation-at-upcoming-investor-conferences-300266243.html

SOURCE Sangamo BioSciences, Inc.